Immunostimulatory monoclonal antibodies for cancer therapy
Immunostimulatory monoclonal antibodies for cancer therapy
Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results
time, versus-host-disease, cancer, molecules, antigen-4 blockade, immune-responses, model, dendritic cells, phase-i trial, gene-therapy, immunotherapy, enhances antitumor immunity, monoclonal antibody, regulatory t-cells, responses, 4-1bb ligand, models, ctla-4 blockade, monoclonal-antibodies, metastatic melanoma
95-106
Melero, Ignatio
7e572737-6b98-4f1f-b6d0-71c64dbdf58a
Hervas-Stubbs, Sandra
888be94e-ac0b-4b96-bc2c-d4442f487735
Glennie, Martin
9f6f0eff-4560-48c2-80cd-0ec116110ded
Pardoll, Drew M.
edbdb758-cb18-4421-aaaa-8f7059e75c3b
Chen, Lieping P.
ccb2ce37-1ea9-4864-a3b8-7d4692041aa1
February 2007
Melero, Ignatio
7e572737-6b98-4f1f-b6d0-71c64dbdf58a
Hervas-Stubbs, Sandra
888be94e-ac0b-4b96-bc2c-d4442f487735
Glennie, Martin
9f6f0eff-4560-48c2-80cd-0ec116110ded
Pardoll, Drew M.
edbdb758-cb18-4421-aaaa-8f7059e75c3b
Chen, Lieping P.
ccb2ce37-1ea9-4864-a3b8-7d4692041aa1
Melero, Ignatio, Hervas-Stubbs, Sandra, Glennie, Martin, Pardoll, Drew M. and Chen, Lieping P.
(2007)
Immunostimulatory monoclonal antibodies for cancer therapy.
Nature Reviews Cancer, 7 (2), .
(doi:10.1038/nrc2051).
Abstract
Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results
This record has no associated files available for download.
More information
Published date: February 2007
Keywords:
time, versus-host-disease, cancer, molecules, antigen-4 blockade, immune-responses, model, dendritic cells, phase-i trial, gene-therapy, immunotherapy, enhances antitumor immunity, monoclonal antibody, regulatory t-cells, responses, 4-1bb ligand, models, ctla-4 blockade, monoclonal-antibodies, metastatic melanoma
Identifiers
Local EPrints ID: 62840
URI: http://eprints.soton.ac.uk/id/eprint/62840
ISSN: 1474-175X
PURE UUID: 19f3d18a-dad1-41f6-84f8-0a0c66a98e56
Catalogue record
Date deposited: 11 Sep 2008
Last modified: 15 Mar 2024 11:33
Export record
Altmetrics
Contributors
Author:
Ignatio Melero
Author:
Sandra Hervas-Stubbs
Author:
Drew M. Pardoll
Author:
Lieping P. Chen
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics